Fact checked by Nick Blackmer I was first told that I was at higher risk for fatty liver disease in 2005. I had never heard ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...

Aroosha Sarrafi tells Health her story of getting diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...